192711-20-9

Usage

Uses

Used in Pharmaceutical Research:
2-(4-nitro-1H-pyrazol-3-yl)pyridine is used as a starting material or reagent for the synthesis of various compounds, particularly in the development of new pharmaceuticals. Its unique structure and reactivity allow for the creation of diverse molecules with potential therapeutic applications.
Used in Chemical Reactions:
In the field of organic chemistry, 2-(4-nitro-1H-pyrazol-3-yl)pyridine serves as a versatile reagent in various chemical reactions. Its nitro group can participate in a range of reactions, such as reduction, substitution, and coupling, enabling the formation of new compounds with different functional groups and properties.
Used in Research and Development:
2-(4-nitro-1H-pyrazol-3-yl)pyridine is employed in research and development settings to explore its potential applications and properties. Its presence in both the pyridine and pyrazole chemical families makes it an interesting subject for studying the effects of structural variations on chemical behavior and reactivity.

Upstream product

• 75415-03-1 2-(1H-pyrazol-3-yl)pyridine 

Downstream Products

• 896467-81-5 3-(pyridin-2-yl)-1H-pyrazol-4-amine 

Relevant academic research and scientific papers

COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME

Disclosed herein are embodiments of a method for treating or preventing cytokine release syndrome (CRS). In certain embodiments, the method comprises administering a compound, or a salt, solvate, prodrug or pharmaceutical composition thereof, to a subject experiencing, or at risk of developing, CRS. The compound may be a kinase inhibitor, such as a JAK inhibitor and/or an IRAK inhibitor, and/or the compound may have a structure according to Formulas I, III, IV or VII. And the method may comprise administering the compound to a subject who is has received, is currently receiving, and/or will be receiving a cell therapy.

PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS

Disclosed embodiments of the formula below concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.

PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES

The invention provides a compound of the formula (I): for use in medicine: or salts or tautomers or N-oxides or solvates thereof; wherein R1 is an optionally substituted heterocyclic group having from 3 to 12 ring members provided that the cyclic group joined to the pyrazole contains at least one heteroatom selected from N, O or S; A is a bond or -Y-(B)n-; B is C=O, NRg(C=O) or O(C=O) wherein Rg is hydrogen or C1-4 hydrocarbyl optionally substituted by hydroxy or C1-4 alkoxy; n is 0 or 1; Y is a bond or an alkylene chain of 1,2 or 3 carbon atoms in length; R2 is hydrogen; halogen; C1-4 alkoxy (e.g. methoxy); or a C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy (e.g. methoxy); R3 is selected from optionally substituted carbocyclic and heterocyclic groups having from 3 to 12 ring members or an optionally substituted C1-8 hydrocarbyl group; with the proviso that R1 is not formula (II): where X, R3’ and R4’ are defined in the claims.